瑞典COPD患者吸入糖皮质激素与骨质疏松及骨折风险:ARCTIC研究
COPD患者骨质疏松相关事件发生率为19.9%,高于对照的12.9%(p<0.0001);高剂量ICS与骨质疏松相关事件风险比1.52(95%CI 1.24-1.62),低剂量为1.27(95%CI 1.13-1.56)。
要点
- COPD患者骨质疏松相关事件风险高于匹配对照人群。
- 高剂量ICS使用与骨质疏松相关事件风险进一步升高相关。
- ICS对骨健康的影响呈剂量效应关系。
核心结论
- COPD患者骨折和骨质疏松风险较高,高剂量ICS使用进一步增加该风险。
研究设计与样本
- 基于瑞典52家初级保健中心2000至2014年电子病历与全国健康登记链接数据的匹配对照研究。
主要发现
- 随访期间19.9%的COPD患者至少发生一次骨质疏松相关事件,匹配对照为12.9%(p<0.0001)。
- COPD患者中高剂量ICS与任何骨质疏松相关事件的风险比为1.52(95%CI 1.24-1.62)。
- 低剂量ICS与任何骨质疏松相关事件的风险比为1.27(95%CI 1.13-1.56),参照为未使用ICS的COPD患者。
- 全部四种特定骨质疏松相关事件均呈现类似的剂量相关不良效应。
关键数值与推荐
- 高剂量ICS:任何骨质疏松相关事件风险比1.52(95%CI 1.24-1.62)。
- 低剂量ICS:任何骨质疏松相关事件风险比1.27(95%CI 1.13-1.56)。
- COPD患者骨质疏松相关事件发生率19.9%,匹配对照12.9%(p<0.0001)。
临床怎么用
- COPD患者应评估骨折和骨质疏松风险,尤其在使用ICS时。
- 高剂量ICS使用者需关注骨健康监测与风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The effect of inhaled corticosteroids (ICS) on the risk of osteoporosis and fracture in patients with chronic obstructive pulmonary disease (COPD) remains uncertain. The aim of this study was to assess this risk in patients with COPD.Electronic medical record data linked to National Health Registries were collected from COPD patients and matched reference controls at 52 Swedish primary care centres from 2000 to 2014. The outcomes analysed were the effect of ICS on all fractures, fractures typically related to osteoporosis, recorded osteoporosis diagnosis, prescriptions of drugs for osteoporosis and a combined measure of any osteoporosis-related event. The COPD patients were stratified by the level of ICS exposure.A total of 9651 patients with COPD and 59 454 matched reference controls were analysed. During the follow-up, 19.9% of COPD patients had at least one osteoporosis-related event compared with 12.9% of reference controls (p<0.0001). Multivariate analysis in the COPD population demonstrated a dose-effect relationship, with high-dose ICS being significantly associated with any osteoporosis-related event (risk ratio 1.52 (95% CI 1.24-1.62)), while the corresponding estimate for low-dose ICS was 1.27 (95% CI 1.13-1.56) compared with COPD patients not using ICS. A similar dose-related adverse effect was found for all four of the specific osteoporosis-related events: all fractures, fractures typically related to osteoporosis, prescriptions of drugs for osteoporosis and diagnosis of osteoporosis.We conclude that patients with COPD have a greater risk of bone fractures and osteoporosis, and high-dose ICS use increased this risk further.
引用
- Janson C, Lisspers K, Ställberg B, et al. Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study. Eur Respir J. 2021. PMID: 32972982. doi:10.1183/13993003.00515-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。